What Are the New Treatments for Hereditary Elliptocytosis?

While the traditional treatment for hereditary elliptocytosis (HE) has been limited to observation, folic acid supplements, or surgical removal of the spleen (splenectomy) ^[1][2], new therapies are on the horizon. Researchers are currently investigating a new class of oral medications called pyruvate kinase (PK) activators—most notably a drug called mitapivat—which aim to improve the health, stability, and survival of red blood cells ^[3][4]. These advancements offer hope for a future where patients with severe HE—those experiencing significant anemia, frequent need for blood transfusions, or complications like gallstones ^[1]—might have non-surgical options to manage their condition.

How New Medications Target Red Blood Cell Health

In HE, the abnormal elliptical shape of the red blood cells makes them fragile and prone to breaking down too early in the bloodstream or spleen, a process known as hemolysis. Medications like mitapivat work differently than traditional supportive care. Mitapivat is an oral drug that activates an enzyme in red blood cells called pyruvate kinase ^[5]. By boosting this enzyme’s activity, the drug increases the cell’s production of adenosine triphosphate (ATP), which acts as the primary energy source for the cell ^[6][7]. This energy boost helps to stabilize the red blood cell membrane, reducing the rate at which the cells break down and improving overall red blood cell survival ^[4].

Current Clinical Trials and Research

Mitapivat is already an approved medication for another red blood cell disorder called pyruvate kinase deficiency, and it is being actively studied for hemoglobin disorders like sickle cell disease and thalassemia ^[8][9].

For red blood cell membrane disorders related to HE, such as hereditary spherocytosis, preclinical laboratory studies in mouse models have shown that mitapivat can significantly improve anemia ^[10]. Importantly, these early studies suggest that the medication could be as effective as a splenectomy at improving red blood cell health, without the need for invasive surgery ^[10].

Currently, a Phase 2 clinical trial known as the SATISFY trial (NCT05935202) is evaluating the safety and effectiveness of mitapivat in adult patients with red blood cell membranopathies (disorders of the red blood cell membrane) ^[11]. While HE falls under the umbrella of membranopathies, trials often focus heavily on related conditions like hereditary spherocytosis. If you are interested in participating, you can search for the trial identifier “NCT05935202” on ClinicalTrials.gov to find enrollment centers and discuss with your doctor if your specific HE profile qualifies ^[11].

Understanding the Safety of New Therapies

While the potential of PK activators like mitapivat and etavopivat ^[12] represents a significant shift toward targeted medical treatments ^[13], these are powerful medications with known risks. In patients who currently take mitapivat for pyruvate kinase deficiency, it is generally well-tolerated, but it has been associated with side effects such as insomnia, back pain, nausea, and rare reports of bone fractures ^[14][15].

Crucially, because mitapivat fundamentally changes how red blood cells process energy, suddenly stopping the medication can cause a metabolic rebound that leads to acute hemolysis—a rapid and dangerous breakdown of red blood cells. Any future use of these medications for HE would require strict adherence and careful medical supervision when starting or stopping the drug.